Stevanato logo

Stevanato

STVN | NYSE
Chart Builder DCF Calculator
$15.53
-$0.27 (-1.71%)
At close: Nov 16, 2026, 4:00 PM ET
$15.53
$0.00 (0.00%)
After-hours: Nov 16, 2026, 4:00 PM ET
-1.71%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
54.3
-1.0 pts
Fundamentals Strong
Market Sentiment Neutral
Moat Narrow
Sector Rank #199/1021 (Top 19%)

Key Statistics

Market Data

Market Cap $4.24B
1D Range
15.12 15.90
52W Range
13.21 23.43

Valuation (TTM)

PE 26.21
PB 2.35
EV/EBITDA 13.38

Valuation (NTM)

Forward PE 23.92
Forward PEG 2.01
Price Target $24.00
Loading financial charts...

Profile

Stevanato Group S.p.A. is dedicated to engineering, manufacturing, and distributing integrated solutions for the pharmaceutical and healthcare sectors. Its core offerings span a wide array of products...

Sector Healthcare
Employees 6,010
IPO Date Jul 16, 2021
Fiscal Year January - December

Latest News

Stevanato Group to Participate in Upcoming Investor Conferences

16 hours ago · gurufocus.com

Stevanato Group to Participate in Upcoming Investor Conferences
Stevanato Group (STVN) Shareholder Investigation Following Stock Decline – Kehoe Law Firm, P.C.

13 days ago · globenewswire.com

Stevanato Group (STVN) Shareholder Investigation Following Stock Decline – Kehoe Law Firm, P.C.
Stevanato Group Q3 Earnings Call Highlights

13 days ago · marketbeat.com

Stevanato Group Q3 Earnings Call Highlights
Stevanato Group S.p.A. Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Stevanato Group S.p.A.

13 days ago · prnewswire.com

Stevanato Group S.p.A. Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Stevanato Group S.p.A.
Stevanato Group S.p.A. (STVN) Q3 2026 Earnings Call Transcript

13 days ago · seekingalpha.com

Stevanato Group S.p.A. (STVN) Q3 2026 Earnings Call Transcript
Stevanato Group (STVN) Surpasses Q3 Earnings and Revenue Estimates

14 days ago · zacks.com

Stevanato Group (STVN) Surpasses Q3 Earnings and Revenue Estimates
Stevanato Group Delivers 8% Revenue Growth for the Third Quarter of Fiscal 2026

14 days ago · businesswire.com

Stevanato Group Delivers 8% Revenue Growth for the Third Quarter of Fiscal 2026
Conestoga Small Cap Composite Q3 2026 Portfolio Activity

21 days ago · seekingalpha.com

Conestoga Small Cap Composite Q3 2026 Portfolio Activity
Stevanato Group and Aptar Pharma Collaborate to Help Accelerate Pre-Filled Syringe System Selection

21 days ago · businesswire.com

Stevanato Group and Aptar Pharma Collaborate to Help Accelerate Pre-Filled Syringe System Selection
Stevanato Group to Report Third Quarter 2026 Financial Results on November 3, 2026

27 days ago · businesswire.com

Stevanato Group to Report Third Quarter 2026 Financial Results on November 3, 2026

Earnings

Latest Earnings
Nov 3, 2026
EPS
$0.18
Beat +1.41%
REV
$369.42M
Beat +1.69%
Next Earnings
Mar 3, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
5
Consensus
Hold
Price Target
$24.00
Upside
+54.54%
Buy (2)
Hold (3)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.